LQDA stock forecast
Our latest prediction for Liquidia Technologies, Inc.'s stock price was made on the July 2, 2020 when the stock price was at 7.79$.
In the short term (2weeks), LQDA's stock price should outperform the market by 0.12%. During that period the price should oscillate between -10.81% and +13.50%.
In the medium term (3months), LQDA's stock price should underperform the market by -10.76%. During that period the price should oscillate between -44.30% and +28.37%.Get email alerts
Create a solid portfolio with LQDA
About Liquidia Technologies, Inc.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -2.24$ per share.
The book value per share is -0.85$
Three months stock forecastJuly 2, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|